Molecure S.A. MOC.WA · Stock Open Molecure S.A. in new tab
Analyst price targets
Recent rating changes, newest first
Molecure S.A. Analysis (MOC.WA)
Is Molecure S.A. a good investment? Molecure S.A. (MOC.WA) is currently trading at 6.69 PLN. Market analysts have a consensus price target of 13.10 PLN. This suggests a potential upside from current levels.
Earnings Schedule: Molecure S.A. is expected to release its next earnings report on Sept. 30, 2026.
Investor FAQ
Does Molecure S.A. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Molecure S.A.?
Molecure S.A. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Sept. 30, 2026. The company currently has a trailing EPS of -0.99.
Company Profile
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
Community Discussion